Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adjusted EPS View
By Rob Curran
Boston Scientific said its first-quarter net income roughly doubled as demand continued to grow worldwide for its stents, catheters and other cardiology devices, but the company cut its adjusted earnings growth projection for the year.
The Marlborough, Mass., medical-device maker posted first-quarter earnings of $1.34 billion, or 90 cents a share, up from $674 million, or 45 cents a share, a year earlier.
Excluding certain one-off items, the company logged first-quarter adjusted earnings of 80 cents a share, edging the average Wall Street target of 79 cents a share, as provided by FactSet.
Sales rose 12% to $5.2 billion, topping the mean analyst estimate of $5.17 billion, as per FactSet. Sales of cardiology devices rose 14% to $3.5 billion, while sales at its MedSurg surgery equipment unit rose 7.8% to $1.7 billion. Sales grew in all regions, with the Latin America and Canada region seeing a 19% increase.
For the second quarter, the stent maker forecast adjusted earnings in a range between 82 cents and 84 cents a share on sales growth of 5.5% to 7.5%. On an organic basis, excluding certain skew factors such as foreign exchange, the company targeted sales growth between 5% and 7%.
Boston Scientific cut its projection for 2026 adjusted earnings to a range between $3.34 and $3.41 a share from a prior estimated range between $3.43 and $3.49 a share. Analysts targeted adjusted earnings of $3.45 a share for the year.
For 2026, the company projects sales growth in a range between 7% and 8.5%, which translates to $21.78 billion at the high end, based on 2025 sales of $20.07 billion. On average, analysts anticipate sales of $22.24 billion for 2026. Boston Scientific expects sales to grow 6.5%-to-8% on an organic basis.
In February, it had targeted sales growth for the year between 10.5% and 11.5%, or between 10% to 11% on an organic basis.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
April 22, 2026 07:22 ET (11:22 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States